Title: Change in antimicrobial resistance of clinical isolates of Acinetobacter baumannii from 2005 to 2011
Abstract: OBJECTIVE To investigate the distribution of Acinetobacter baumannii and the change in the drug resistance so as to guide the reasonable use of antibiotics and reduce the drug resistance.METHODS The distribution and drug resistance rates of the clinical isolates of Acinetobacter baumannii were statistically analyzed from 2005 to 2011.RESULTS A total of 1973 strains of A.baumannii were isolated during the past seven years,among which 85.4% were isolated from the respiratory tract,3.7% from urine,3.2% from secretions,2.1% from blood,and 2.1% from drainage fluid.35.0% of the strains were isolated from the ICUs and 65.0% were isolated from the non-ICU departments.The detection rates of both the A.baumannii and the MDA increased year by year.The overall drug resistance rate of the strains isolated from the ICU was higher than that of the strains isolated from the non-ICU departments;the average drug resistance rates of the A.baumannii to cefperazonesulbactam imipenem,and meropenem were 22.4%,28.7%,and 29.2%,respectively,which were the preferred choice for the empirical treatment;the average resistance rates to ceftazidime,ceftriaxone,and cefepime were 46.4% and 44.5%,respectively;the average resistance rates to ticarcillin-clavulanate,piperacillin-tazobactam,and trimethoprim-sulfamethoxazole were 44.3%,37.1%,and 52.2%,respectively;the average resistance rates to amikacin and levofloxacin were 28.1%and 36.8%,respectively.CONCLUSION The constituent ratios and the drug resistance rate of the A.baumannii strains show an upward trend during the seven years.It is of positive significance to formulate the effective infection control measures and prevent the outbreak and epidemic of infections by strengthening the bacteriological monitoring and dynamics of the cases with nosocomial infections.
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot